Literature DB >> 3102050

Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma.

V B Grossie, D M Ota, J A Ajani, K Nishioka.   

Abstract

The effect of a continuous i.v. infusion of alpha-difluoromethylornithine (DFMO) on the polyamine metabolism of tumor and normal host tissue was determined. Non-tumor-bearing Fischer 344 rats or rats bearing a transplantable fibrosarcoma received continuous infusions of DFMO through a central venous catheter at three dose levels. Treatment with DFMO resulted in a time- and dose-dependent, cytostatic effect on the growth of the tumor. In fibrosarcoma-bearing rats the tumor putrescine levels were reduced after 6 and 12 days of DFMO treatment. Tumor spermidine levels were consistently reduced after 6 and 12 days of treatment with the reduction being dose dependent. The decrease in tumor ornithine decarboxylase activity was dose dependent. Erythrocyte putrescine levels were decreased in tumor- and non-tumor-bearing rats, suggesting that DFMO reduces the tumor contribution to the erythrocyte pool. Erythrocyte spermidine levels of fibrosarcoma- and non-tumor-bearing rats were elevated at the lower DFMO doses administered for 12 days but returned to normal as the dose was increased. Erythrocyte spermine levels were elevated in both groups of rats at all DFMO doses. Although normal host tissue weights were not affected by treatment with DFMO, the putrescine and spermidine levels of liver, spleen, and kidney and ornithine decarboxylase activity of the liver and kidney were decreased. These data demonstrate that i.v. DFMO has a cytostatic effect toward a rapidly growing fibrosarcoma associated with the depletion of both tumor putrescine and spermidine levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102050

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.

Authors:  J A Ajani; D M Ota; V B Grossie; J L Abbruzzese; J S Faintuch; Y Z Patt; D E Jackson; B Levin; K Nishioka
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

3.  Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.

Authors:  V B Grossie; D M Ota; J A Ajani; K Nishioka
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

4.  Effect of alpha-difluoromethylornithine on the polyamine levels and proliferation in two transplantable tumours.

Authors:  M R Alison; C E Sarraf; V E Emons; S A Hill; M Maghsoudloo; G M Murphy
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.

Authors:  Altaf Mohammed; Naveena B Janakiram; Venkateshwar Madka; Rebekah L Ritchie; Misty Brewer; Laura Biddick; Jagan Mohan R Patlolla; Michael Sadeghi; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.